

An LC/MS Metabolomics Discovery Workflow for Malaria-Infected Red Blood Cells Using Mass Profiler Professional Software and LC-Triple Quadrupole MRM Confi rmation

Application Note

Clinical Research

Authors

Theodore Sana Steve Fischer Shane Tichy

Agilent Technologies, Inc. Santa Clara, CA USA

Abstract

The utility of a combined un-targeted discovery-based LC/MS and targeted confi rmation LC/MS/MS approach for mining metabolomics data was demonstrated using malaria-infected red blood cells as a model system. Several compounds, including arginine, citrulline, and ornithine, were identifi ed as metabolites whose biosynthesis was altered in erythrocytes infected by the malaria parasite.



Introduction

A metabolomics approach was used to demonstrate the utility of combined untargeted (discovery) LC/MS and targeted (confi rmation) LC/MS/MS workfl ow (Figure 1) to find metabolites that are present at different relative levels in cultured non-infected red blood cells (NRBC), versus malariainfected red blood cells (IRBC). Untargeted data mining of LC/Q-TOF MS data resulted in the detection of thousands of metabolites which were subsequently analyzed for statistical differences in Mass Profi ler Professional (MPP) software to discover patterns of association between sample groups. Differential metabolites were queried against the **METLIN Personal Compound Database** for identification. As an example of the powerful analytical capabilities of the software, the Molecular Feature Extraction (MFE) algorithm detected m/z 175.1190, corresponding to the amino acid arginine, to be significantly suppressed or absent in IRBC relative to NRBC samples. The use of a pathway analysis tool in MPP highlighted the arginine metabolism pathway that also includes the physiological amino acids ornithine

Statistics Senarate Find Identify pathwavs + detect & quantitate & visualize Guided & Pathway GC/MSD GCMS MH Qual Advanced **ID Browser** Analysis GC/000 Module workflows Untargeted "Naïve" Data Mining LC/Q-TOF MFE (Discover) LCMS **Targeted Data Mining** FbF LC/000 (Confirm) **Mass Profiler Pro**

A combined un-targeted (discovery) LC/MS and targeted (confirmation) LC/MS/MS metabolomics workflow

Figure 1. A graphical representation of the analytical workflow used for the study of malaria infected erythrocytes. Agilent metabolomics workflow from separation to pathway analysis typically involves both GC/MS and LC/MS analyses. Molecular feature extraction (MFE) and Find by Formula (FbF) are two different algorithms used for finding peaks. All results files generated by the different analytical platforms can be imported into Mass Profiler Professional (MPP) for statistical analysis and visualization.

and citrulline. Subsequent "targeted" data mining of the original data using Extracted Ion Chromatograms (EICs) corresponding to these two compounds revealed that they were also present at low levels across all samples and that arginine metabolism was probably affected in IRBCs. This finding was subsequently tested by multiple reaction monitoring (MRM) assays targeting both samples and standards for arginine, citrulline, and ornithine on an Agilent 6460 Triple Quadrupole LC/MS with Jet Stream technology. Due to the increased sensitivity of this platform, we were able to confirm that arginine levels are significantly reduced, whereas citrulline and ornithine levels were elevated in IRBCs.

Experimental

Study design

Two separate groups of RBC culture samples (total n=24): Control (NRBC) and infected (IRBC) cells at approximately 10% parasitemia were processed using a previously described sample extraction method for RBCs¹. The extraction solvent pH was varied to either pH 2, 7 or 9 in a biphasic solution of methanol/water/chloroform to optimally drive biphasic separation in each of the quadruplicate samples per pH sub-group (condition), and to maximize metabolite recovery in the aqueous phase.

Cell culture

The 3D7 strain of *Plasmodium falciparum* parasite was grown in asynchronous erythrocytes, maintained in RPMI 1640 medium supplemented with 25 mM HEPES, 20 mM sodium bicarbonate, 370 μ M hypoxanthine, and 0.5% AlbuMAX (Invitrogen) at 5% hematocrit. The cultures were incubated under 90% N₂, 5% O₂, and 5% CO₂ at 37°C. A 0.5 mL aliquot of erythrocyte culture was harvested for each sample 24 hours after parasite exposure, quenched with methanol, and metabolites extracted according to the protocol.

Sample filtering

In order to remove residual proteins that can cause significant detection interference in the LC/MS step, the aqueous phase extracts of the cell cultures were filtered through 0.2 μ m Pall Nanosep MF filters (Pall Life Sciences, Ann Arbor, MI), followed by 10 kDa Pall Nanosep Pall centrifugal device filters, dried under vacuum, and re-suspended in 100 μ L of 50:50 methanol:water, 0.2% acetic acid. One microliter was injected into each LC system.

Instruments

This study was performed in two parts: "un-targeted" discovery and "targeted" confirmation. Un-targeted discovery was carried out using reverse phase chromatography on an Agilent 1200 Series Rapid Resolution LC (RRLC) system equipped with a binary pump, autosampler with chiller and thermostatted column compartment, and coupled with an Agilent 6520 Accurate-Mass Q-TOF LC/MS with a dual ESI source (**Table 1**). Confirmation of the discovery results was performed using Aqueous Normal Phase (ANP) chromatography on an Agilent 1200 Series RRLC system equipped with a binary pump, vacuum degasser, high performance thermostatted autosampler and a thermostatted column compartment, and connected to an Agilent 6460 Triple Quadrupole LC/MS System with Jet Stream technology (**Table 2**).

Table 1. LC and Q-TOF MS Conditions

LC Run Conditions	
Column	Guard column: ZORBAX SB-C8, 2.1 x 30 mm, 3.5 µm (P/N 873700-936) Analytical Column: ZORBAX SB-Aq, 2.1 x 50 mm, 1.8 µm (P/N 827700-914)
Column temperature	60°C
Injection volume	1 µL
Autosampler temperature	4°C
Needle wash	3 sec in wash port
Mobile phase	A = 0.2% acetic acid in water B = 0.2% acetic acid in methanol
Flow rate	0.6 mL/min
Linear gradient	 2% methanol to 98% methanol in 13 min 6 min hold at 98% methanol Stop time: 19 min Post time: 5 min

Q-TOF MS Conditions

lon mode	Both positive and negative
Drying gas temperature	250°C
Drying gas flow	10 L/min
Nebulizer pressure	45 psig
Capillary voltage	4000 V (positive mode) / 3500 V negative mode
Fragmentor	140 V
Reference Delivery	Agilent 1100 isocratic pump with 100:1 splitter (P/N G1607-60000)
Reference pump flow	1 mL/min for 10 μ L/min to nebulizer
Reference ions	Positive mode: 121.050873 and 922.009798 Negative mode: 119.036320 and 966.000725
Instrument mass range	1700 Da
Acquisition rate	2 Hz
TOF spectra mass range	50 to 1000 <i>m/z</i>
Data storage	Centroid
Threshold	100
Instrument mode	Extended Dynamic Range

Table 2. LC and Triple Quadrupole MS Conditions

LC Run Conditions	
Column	Cogent Microsolv Diamond Hydride 100Å 4µm 2.1 x 150 mm
Column temperature	45°C
Injection volume	1 μL
Autosampler temperature	4°C
Needle wash	3 seconds in wash port
Mobile phase	A = 0.1% formic acid in water B = 0.1% form acid in acetonitrile
Flow rate	0.4 mL/min
Linear gradient	 100% acetonitrile to 65% acetonitrile in 2.80 min 2.2 min hold at 65% acetonitrile Stop time: 5 min Post time: 5 min

Triple Quadrupole MS Conditions					
lon mode	Positive				
Drying gas temperature	300°C				
Drying gas flow	6 L/min				
Sheath gas temperature	275°C				
Sheath gas flow	11 L/min				
Nebulizer pressure	45 psi				
Capillary voltage	4000 V (Positive mode)				
Nozzle voltage	500 V				
Delta EMV	200 V				
MRM	175.0 -> 70.1; 133.0 -> 166.1; 176.0 -> 159.1				

Data acquisition and analysis

MassHunter Qual was used in a naïve, un-targeted data-mining approach to analyze the LC/MS-ESI TOF data in the discovery phase. The resulting files were then imported into Mass Profiler Professional for analysis. Agilent MassHunter Optimizer Software (B.02.00) was used with the triple quadrupole LC/MS system for identifying the most abundant multiple MRM transitions along with the associated fragmentor voltages and collision energies. MassHunter Workstation (version B.02.01) was utilized for data acquisition and MassHunter Quantitative Analysis Software (version B.04.00) was used for data processing.

Results and Discussion

Un-targeted data mining

Metabolomics workflows typically include sample preparation, separation, data collection, feature finding, statistical analysis and compound identification. The aqueous phase extracts for control (NRBC) and infected red blood cells (IRBC) were first analyzed by LC/MS-ESI TOF in both (+/-) ion modes. The data files were processed in MassHunter Qual using (1) a naïve, un-targeted data mining approach, and (2) a targeted data mining approach using a list of known compounds. To accomplish (1), the MFE algorithm was used which processes data files very quickly and is the method of choice for an un-targeted discovery workflow. Each of the thousands of extracted compound chromatograms was automatically drawn by the software and user-inspected before a Compound Exchange File (.cef) was generated for each sample file.

After data processing in MassHunter Qual, the .*cef* files were imported into MPP for analysis. The "Guided workflow" was selected from the menu, which is a simple way to follow in a step-by-step fashion a series of analytical steps including feature alignment, data file grouping, filtering, quality control, statistical analysis, and compound identification. Pathway analysis was performed as part of the "Advanced workflow".

Determining variability between various conditions for NRBC and IRBC groups

Data filtering:

The data was filtered to create entity lists based on the number of entities detected in at least one condition of the NRBC and IRBC sample replicates. The results are summarized in Table 3, which reveal the average number of entities per group in ESI+, ESI- and APCI+ modes, across pH 2, pH 7 and pH 9 extracted samples. For a given condition (i.e. pH), filtered entity lists were created based on the number of entities that passed the 100% or 75% sample replicate thresholds. The particular threshold to use depends on the number of replicates. Due to the limited number of biological replicates in this experiment, the entity list using stringent filter conditions (100%) was used as input for the subsequent step, "Filter by sample variability". In this case, entities displaying a coefficient of variation (CV) of the signal abundances of greater than 100% per condition were filtered away. This ensured that only reproducible data were analyzed in subsequent steps.

Condition	pH2_ESI	pH7_ESI	pH9_ESI	pH2_ESI	pH7_ESI	pH9_ESI	pH2_APCI	pH7_APCI	pH9_APCI
	neg	neg	neg	pos	pos	pos	pos	pos	pos
NRBC	1433	915	1267	2029	1401	2626	1128	463	500
IRBC	1327	1151	1232	2042	1542	2661	665	460	652
	1			r r					
Rel Freq. 75%	1660	1282	1412	2175	1838	2822	916	502	679
Rel Freq. 100%	1259	917	1086	1550	1247	2086	486	342	483
CV < 100%	781	547	649	936	662	1083	284	235	271

Table 3. The number of features detected in each condition, NRBC and IRBC, is summarized for samples extracted under different solvent pHs, using both ESI and APCI sources and polarities

Principal component analysis (PCA): PCA highlighted the difference between NRBC and IRBC samples extracted under the various pH conditions. **Figure 2** shows the distribution of the samples along the 3 major principal components. The most significant difference observed was the separation of samples based on solvent pH, confirming a previously published observation for RBCs¹. Thus, these results suggest that one can maximize metabolite coverage by including additional aqueous solvent extractions at pH 2 and pH 9, as well as pH 7. Furthermore, a closer inspection of the PCA plot for pH 7 extracts, by rotation about the axes, highlighted clear separation between IRBC and NRBC samples.

Identify variability between groups with Principal Component Analysis



Figure 2. Principal Component Analysis of metabolite data from biological replicate samples highlights variability in abundance profiles between NRBC and IRBC for pH 7 extracted samples.

Determining significant abundance differences of compounds across groups

Identification

MPP includes a convenient, integrated ID Browser that enables accurate mass compound matching of the list of differential metabolites to the METLIN database. For masses that did not match a compound in the database, an Agilent empirical formula calculator, called Molecular Formula Generator (MFG), was used to calculate the formula with the 'best' match based on the mass accuracy of the isotope masses and their ratios. The compound list displayed results for database matches < 5 ppm. In addition to an MS spectrum and structure, the base peak abundance and the abundances for all the isotopes, including any specified adducts, are summarized (Figure 3). One of the compounds, m/z 175.1190, matched the amino acid arginine. After identifying compounds using the ID browser, MPP automatically annotated the entity list and projected the compound names onto the graphical plots and pathways for visualization.

Statistical analysis

Since PCA had shown group differences based on extracted metabolite abundance profiles when samples were extracted at different pH values, the results of each pH extract were analyzed independently to find entities with statistically significant abundance differences between NRBC and IRBC. A useful tool for visualizing differential abundance between any two different conditions is the Volcano plot, which provides a visual summary of *p*-values and fold-change values,

adding statistical significance to the interpretation of the results. As an example, for the ESI+, pH 7 extracted samples, the results for a differential abundance analysis of NRBC and IRBC are summarized in Figure 4, where the Volcano scatter plot is shown using Fold Change (FC) and *p*-value on each axis. A summary table for all entities revealed the number of differential entities based on FC and *p*-value. For example, there were 69 entities that had a p < 0.05 and FC > 2. Inspection of a separate table provided details of the actual FCs, *p*-values and the direction of regulation for each significant entity, based on the results of an unpaired t-test between NRBC and IRBC samples. From this table we were able to see that the result for one of the 'identified' compounds, arginine, was highly significant, with an absolute FC=16 and down regulation. This means that using MFE, its presence was detected in NRBC samples and not detected in IRBC samples.

ID Browser in Mass Profiler Professional facilitates identification of significant abundance differences



Figure 3. ID Browser results for a list of differential compounds reveals METLIN database matches for several compounds, including arginine. MassHunter ID Browser was used for identification (METLIN database annotation) of compounds from an entity list generated in MPP. The result for mass 174.1117 matched (< 5 ppm) a single compound, arginine, in the METLIN database. In addition to the formula, database match score, Name, KEGG and CAS ID, the figure for the mass spectrum, the isotope abundances associated with the base peak, and a compound structure viewer based on the MOL file are included.

Volcano plots help visualize differential abundance

selected Test :	T Test unpaired					
-value computation:	Asymptotic					
b rulae comparation	1 Symptotic	the shift and				
Multiple Testing Correc	tion: Benjamini-	Hochberg				
Result Summary						
	P all	P < 0.05	P < 0.02	P < 0.01	P < 0.0050	P < 0.0010
FC all	500	d 8	3 75	62	61	60
FC > 1.1	27		75	62	61	
PC > 1.1	37,	8	5 /5	62	61	60
FC > 1.5	14	1 7	B 73	62	61	60
FC > 2.0	8	6	9 67	62	61	60
FC > 3.0	6	6	4 64	61	61	60
Europeand by shares				01	01	/
Expected by chance			1	0	0	
Compound b, ro, rray-r, rr-umyuroxy-c	p-value	Corrected p-value	Absolute regulation	~		0 0 0
26 H56 N2 O5	2.3816215E-4	0.012641525	2.05 up			
42 H80 N2 S	0.0	0.0	16.0 40			
22 H11 CLO18	4.7155714F-4	0.015960395	3.02 down		-	
22 H15 CLN2 O22	9.7900396E-5	0.011442894	3.08 down	2		
57.9858@0.32587498	0.0	0.0	16.0 down			
91.9571#0.3270294	3.0809442E-5	0.006778077	2.63 down	8		
rginine	0.0	0.0	16.0 down	6		e
18 H28 N2 O5 S	0.0	0.0	16.0 down			
13 H9 N9 O5 S	0.0	0.0	16.0 down	g 15		
	0.0	0.0				
56.5236@2.667818	0.0	0.0	16.0 up	- 6		
56.5236@2.667818 10 H18 N6 O 54	0.0	0.0	16.0 up 16.0 up	- April		8
56.5236@2.667818 10 H18 N6 O S4 22 H35 N5 O6 S 21 H11 CLN8 O12 S	0.0	0.0	16.0 up 16.0 up 16.0 up			
56.5236#2.667818 10 H18 N6 0 54 22 H35 N5 06 5 21 H11 Cl N8 012 5 10 H12 N8 54	0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0	16.0 up 16.0 up 16.0 up 16.0 up 16.0 up		1 1 1	
56.5236#2.667818 10 H18 N6 O 54 22 H35 N5 O6 5 21 H11 CI N8 O12 5 10 H12 N8 54 14 H3 CI O9 S2	0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0	16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up			# #
56.5236@2.667818 10 H18 N6 O S4 22 H35 N5 O6 S 21 H11 Cl N8 O12 S 10 H12 N8 S4 14 H3 Cl O9 S2 16 H18 N8	0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0	16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up	*		-
56.5236#2.667818 10 H18 N6 0 54 22 H35 N5 06 5 21 H11 CI N8 012 5 10 H12 N8 54 14 H3 CI 09 52 16 H18 N8 1-(5-Phospho-D-ribosyl)-AMP	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0	16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up	2 percentario 1		•
56.5236#2.667818 10 H18 N6 0 54 22 H35 N5 06 5 21 H11 C1 N8 012 5 10 H12 N8 54 14 H3 C1 09 52 16 H18 N8 1-(5-Phospho-D-ribosyl)-AMP 1-5/Phospho-D-ribosyl)-AMP	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up	Aprox		
56.5236#2.667818 10 H18 No 0 54 22 H35 NS 06 5 21 H11 Cl N8 012 5 10 H12 N8 54 14 H3 Cl 09 52 16 H18 N8 1-(5-Phospho-D-ribosyl)-AMP 13 H17 N3 06 5 + 0.57841176 74.5603@0.6255	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 2.31 down	April 1		
56.5236#2.667818 10 H18 No 0 54 22 H35 NS 06 5 21 H11 C1 NN 012 5 10 H12 NN 54 14 H3 C1 09 52 16 H18 N8 1-(5-Phospho-D-ribosyl)-AMP 13 H17 N3 06 5 + 0.57841176 74.5603#0.6255 15 H2 N2 07 15	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0016418052 0.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 2.31 down 16.0 up	0.3		-
56 52 3692, 567818 10 H18 No O 54 22 H35 NS O6 5 21 H11 C1 No 012 5 10 H12 NB 54 14 H3 C1 09 52 1-(5-Phospho-D-ribosyD-AMP 1-(5-Phospho-D-ribosyD-AMP 13 H17 N3 O6 5 + 0.57841176 74 560200 6255 15 H2 N2 O7 37 037560, 71644443	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 2.31 down 16.0 up 16.0 up 16.0 up	03-		
56.523692,667818 10 H18 No 0 54 22 H35 NS 06 5 11 H11 Cl No 012 5 10 H12 NB 54 14 H3 Cl 09 52 16 H18 NB 1-(5-Phospho-D-ribesy0-AMP 13 H17 N3 06 5 + 0.57841176 74 560309 065 + 0.57841176 74 560309 065 + 0.57841176 74 560309 065 + 0.57841176 70 057500,71644443 50.788440,750375	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up 2.31 down 16.0 up 2.31 down 16.0 up 16.0 up 16.0 up 16.0 up 16.0 up	03-		
56.523692,667818 10118 N6 0 54 22 H35 N5 06 5 110 H12 N6 012 5 10 H12 N8 54 14 H3 CI 09 52 16 H18 N8 1-15-Phospho-D-ribosyl-AMP 13 H17 N3 06 5+ 0.57841176 74.560380 6255 13 H2 N2 07 0.075340,71644443 50.784440,750375 16 H4 CI N3 08 55	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	16.0 up 16.0 up			
156.523692.667818 156.523692.667818 128.183.05.06 128.183.05.06 124.183.05.05 124.183.05.05 124.183.05.05 124.183.05.05 134.173.05.05.05 134.173.05.05 134.124.05 135.124.25 135.124.125.05 124.145.05 125.125.05 124.145.05 125.125.05 125.155.0	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0016418052 0.0016418052 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	16.0 up 16.0 up	4		

Figure 4. The results of a t-test between NRBC and IRBC samples is displayed as a Volcano Plot, revealing the fold-change in abundance as well as p-value of significance for each mass entity in a list of compounds that were 'identified' using ID Browser. The p-value, fold change, and directionality of regulation are also summarized in a table. For example, arginine levels appear to be significantly reduced or absent in IRBC based on the result of log₂ transformation of the abundances, expressed as a ratio.

Hierarchical cluster analysis of entities and conditions

Hierarchical cluster analysis was performed to organize the compounds or entities and replicate samples in the two conditions into clusters based on the similarity of their abundance profiles. This resulted in a hierarchical tree for the identified entities and a hierarchical tree for the conditions, organized into a heat map. The heat map confirmed the separation of the sample replicates for the two conditions. Figure 5 includes the differential abundance pattern for arginine between the IRBC and NRBC groups in the tree, with the branches colored red and blue, respectively.

Figure 5. Hierarchical cluster analysis organized the replicate samples into two distinct clusters based on the similarity of entities' abundance profiles for the NRBC and IRBC conditions. Clustering analysis by entity profiles across sample groups allows for the grouping together of compounds that have similar abundance profiles. This may reveal interesting relationships, as entities that exhibit similar behavior across a set of experimental conditions may share similar reaction pathways.



Hierarchical cluster analysis organizes entities based on similarity of abundance profiles

Targeted data mining of TOF data

Feature extraction algorithms that are un-targeted or naïve can sometimes compromise detection sensitivity. Therefore, we also analyzed the data with the more sensitive EIC-based, "Find by Formula" or FbF algorithm for targeted data mining. **Figure 6** shows two different method editors in MassHunter Qual that are used for un-targeted or naïve data mining (left panel) and targeted data mining (right panel). Targeted data mining of TOF data was achieved in a couple of different ways: (1) a list of compound formulas was created based on literature associated with malaria. The formulas were entered into a new METLIN personal compound database (PCD) for malaria. The database was then queried from within MassHunter Qual against all the sample files to find any matches. The 'best' EIC was integrated and *.cef* files were generated for analysis in MPP; (2) A pathway-specific approach was used in which, for example, the arginine biosynthesis pathway was downloaded in Biopax format (.ow/) from Pathway Commons: http://www.pathwaycommons.org/. The file was loaded into MassHunter Qual and each formula in the pathway was automatically queried against each data file. The masses corresponding to the formulas for both citrulline and ornithine, which participate in the arginine biosynthetic pathway, were found in IRBC and NRBC data by targeted analysis.

Find by Formula (FBF)

Two algorithms for data mining increase the breadth of peak finding



Method Editor: Find Compounds by Molecular Feature X	Method Editor: Find Compounds by Formula - Options X
Method Editor: Find Compounds by Molecular Feature X Image: State Compound Riters Image: State Compound Riters Mass Defect Results Advanced Extraction algorithm Target data type Small molecules (chromatographic) Image: Small molecules (chromatographic)	Method Editor: Find Companels by Formula - Option X A Fonula Source A Fonula Matching Positive lone Negative lone Source of formulas: Cd2448N18 (byte a comma-segerated list of formulas, e.g., "CBH6, CH4") Compound exchange file (CEF): Load BioPax .ow// file Database Mass Huter/databases/Methin.mt Units Mass and retention time (retention time optional) Mass and retention time (retention time required)
"Naïve extraction"	"Targeted extraction"

Figure 6. The algorithms used in MassHunter Qual for finding or extracting the peaks in data acquired in un-targeted mode are shown. The peaks were extracted in either a "naïve" or "targeted" fashion using Find by Molecular Feature (MFE) and Find by Formula (FbF), respectively. The use of two independent methods increases the comprehensiveness of peak finding. The software allows one to change variables for each algorithm located under the different tabs. Furthermore, for targeted analyses the formulas from 'Pathway Commons' for a specific set of compounds were also loaded in an .owl file format, belonging to the citrulline biosynthetic pathway (which includes arginine).

Pathway analysis

Compound annotation using the integrated ID browser in MPP enabled the use of integrated pathway software (Pathway Module) to mine interaction databases provided by Agilent that are created using natural language processing of published literature. It was used in conjunction with the imported Biopax formatted arginine biosynthesis pathway. The pathways were searched using an entity list of differential entities to determine which pathways might be relevant. An interactive pathway viewer revealed the average compound abundances for arginine by sample group (Figure 7).

MRM assays by triple quadrupole LC/MS/MS for pH 7 extracted metabolites

Finally, once several members of the arginine biosynthesis pathway were identified, MRM assays, using the parameters shown in Table 4, were performed on the triple quadrupole LC/MS platform for arginine, ornithine and citrulline to confirm the discovery LC/Q-TOF findings, and to provide quantitative information for the levels of several amino acids in this biosynthetic pathway. Since the reverse phase LC method used for the initial discovery analysis does not retain highly polar metabolites such as arginine, the MRM assay used a hydrophilic method, based on a silica hydride column operated in the Aqueous Normal Phase (ANP) mode.

Pathway software facilitates pathway analysis



Figure 7. Pathway Architect was used to evaluate MS data in biological context by direct navigation between biological pathways and their associated compounds. The average abundance for arginine (Arg) based on the sample group is summarized using an abundance color key in a yellow (IRBC) or blue (NRBC) block.

Table 4. MRM assay parameters

Compound	Precursor lon (<i>m/z</i>)	Product Ion (<i>m/z</i>)	Fragmentor (V)	Collision Energy (V)	Retention Time (min)
Citrulline	176	159	75	6	1.5
Arginine	175	70.1	75	16	2.4
Ornithine	133	116	75	6	2.6

Calibration curves were constructed for arginine, citrulline, and ornithine, using concentrations of 0.1, 1.0 10, 100 and 1000 ng/mL. The Figure 8 inset shows the calibration curve for arginine, and illustrates the excellent linearity obtained with R² values very close to 1.000. Calibration curves for each compound were generated over five orders of magnitude. The three calibration curves were generated using a linear fit, no inclusion through the origin, and a 1/x weighting. Figure 8 also illustrates the differential quantitative results between NRBC and IRBC based on MRM transitions for arginine $(175.0 \rightarrow 70.1)$, ornithine (133.0 \rightarrow 116.1), and citrulline (176.0 \rightarrow 159.1). A summary table (Table 5) lists the relative amounts (pg) of each compound determined from the calibration curves based on a 1 µL injection, the associated standard deviation (SD) for the biological replicates, and a calculated amount of each compound contained in 1 mL of RBC suspension. It is clear that the amount of arginine drops significantly in IRBC relative to NRBC (almost 8-fold). Conversely, the relative amounts of ornithine, and particularly citrulline, were increased in IRBC, indicating a reduction in arginine biosynthesis.

MRM assays on a triple quadrupole LC/MS confirm the abundance findings



Figure 8. LC/MS/MS analysis of pH 7 extracted metabolite samples on a polar silica hydride column confirms the LC/TOF results. The MRM transitions for arginine, citrulline and ornithine are displayed. Standard curves (inset) were built across a wide dynamic range (five logs), which enabled the estimation of the concentrations for each compound in each RBC sample.

C	NRBC				Fold Change		
Compound	pg	SD	pg/mL	pg	SD	pg/mL	(NRBC/IRBC)
Citrulline	2.3	1.6	187.1	26.2	2.4	2093.1	0.1
Ornithine	48.4	6.9	3873.8	75.5	9.0	6041.5	0.6
Arginine	35.6	19.8	2846.9	4.5	6.5	356.5	8.0

Table 5. Relative amounts of each compound extrapolated from the calibration curves

Conclusion

A global metabolomics workflow was used to initially identify several compounds, including arginine, citrulline and ornithine, as metabolites whose biosynthesis was altered in in-vitro cultured erythrocytes infected by the malaria parasite. This example demonstrates that separate algorithms in MassHunter Qualitative data analysis software can be used for finding compounds acquired in an un-targeted or global (MS-only) mode. The data were extracted in an "un-targeted" (i.e. no a priori knowledge of what compounds are present in the sample) fashion, and in a "targeted" fashion using a list of known compounds that were expected to be present/absent in the samples. Initially, the ID Browser in Mass Profiler Professional was used to match mass 174.1117 to arginine in

the METLIN database. This compound was present in NRBC samples only. MPP's Pathway Module was then used to determine biological relevance. Insights gained from the pathway analysis led to recursive interrogation of the data in a targeted fashion. Once a preliminary conclusion was reached from the discovery (global) metabolomics experiment, a targeted analysis was designed for the triple quadrupole LC/MS system to quantify the metabolites identified in the initial data mining experiment: arginine, citrulline and ornithine. This workflow demonstrates how a discovery based approach for mining data can be subsequently performed in a quantitative fashion. The data could also be imported into MPP to verify the biological conclusions on a larger population set.

References

 T. R. Sana, K. Waddell, S. M. Fischer, "A sample extraction and chromatographic strategy for increasing LC/ MS detection coverage of the erythrocyte metabolome," *J Chromatogr B*, 871:314–321, **2008**.

www.agilent.com/chem/ metabolomics

For Research Use Only. Not for use in diagnostic procedures.

Information is subject to change without notice.

© Agilent Technologies, Inc. 2010, 2015 Published in the U.S.A. August 25, 2015 5990-6790EN



Agilent Technologies